Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,183.90 +3.16 (+0.06%) Dow
38,866.77 +14.50 (+0.04%) Nasdaq
16,322.81 -26.43 (-0.16%) Bitcoin USD
62,939.64 -419.79 (-0.66%) CMC Crypto 200
1,309.37 -55.76 (-4.08%)
Akebia Therapeutics, Inc. (AKBA)
| Previous close | 1.4900 |
| Open | 1.5100 |
| Bid | 1.4000 x 200 |
| Ask | 1.4100 x 200 |
| Day's range | 1.3800 - 1.5600 |
| 52-week range | 0.7800 - 2.4800 |
| Volume | |
| Avg. volume | 5,031,722 |
| Market cap | 295.529M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets.
- PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- PR Newswire
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the phy
